Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.47 |
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185164 | 0.93 | GRM5 (0.43) | FFAR1GRM5S1PR1KDM4ELMNA | |
| SCHEMBL14474198 | 0.91 | S1PR1 (0.46) | FFAR1GRM5S1PR1KDM4ELMNA | |
| SCHEMBL16185130 | 0.90 | ABCG2 (0.45) | FFAR1GRM5KDM4ELMNAHTT | |
| SCHEMBL16185138 | 0.90 | GRM5 (0.48) | FFAR1GRM5LMNAMAP4K4 | |
| SCHEMBL16185136 | 0.89 | GRM5 (0.44) | FFAR1GRM5LMNAMAP4K4 | |
| SCHEMBL16185137 | 0.89 | GRM5 (0.46) | FFAR1GRM5LMNAMAP4K4MAPK14 | |
| SCHEMBL14474191 | 0.89 | GRM5 (0.44) | FFAR1GRM5LMNAMAP4K4 | |
| SCHEMBL16185154 | 0.87 | GRM5 (0.42) | FFAR1GRM5S1PR1KDM4ELMNA | |
| SCHEMBL16185147 | 0.87 | FFAR1 (0.43) | FFAR1GRM5S1PR1KDM4ELMNA | |
| SCHEMBL14475260 | 0.85 | GRM5 (0.42) | FFAR1GRM5S1PR1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | FFAR1 4087/4885GRM5 37/4885S1PR1 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.